Page 85 - 2021_06-Haematologica-web

Hyaluronan/CD44-mediated VLA-4 activation in AML
rationale supporting CD44-induced AML differentiation therapy. Leukemia. 2016;30 (12):2397-2401.
26. Charrad RS, Gadhoum Z, Qi JY, et al. Effects of anti-CD44 monoclonal antibodies on dif- ferentiation and apoptosis of human myeloid leukemia cell lines. Blood. 2002;99(1):290-299.
27.Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103(8):2981-2989.
28. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL- expressing leukemic stem cells. Nat Med. 2006;12(10):1175-1180.
29. Bendall LJ, Kortlepel K, Gottlieb DJ. Human acute myeloid leukemia cells bind to bone marrow stroma via a combination of beta-1 and beta-2 integrin mechanisms. Blood. 1993;82(10):3125-3132.
30. Chigaev A, Blenc AM, Braaten JV, et al. Real time analysis of the affinity regulation of alpha 4-integrin. The physiologically activat- ed receptor is intermediate in affinity between resting and Mn(2+) or antibody activation. J Biol Chem. 2001;276(52):48670- 48678.
31. Laufer JM, Legler DF. Beyond migration- Chemokines in lymphocyte priming, differ- entiation, and modulating effector func- tions. J Leukoc Biol. 2018;104(2):301-312.
32. Thankamony SP, Sackstein R. Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci U S A. 2011;108 (6):2258-2263.
33. Chien S, Haq SU, Pawlus M, et al. Adhesion of acute myeloid leukemia blasts to E- selectin in the vascular niche enhances their survival by mechanisms such as Wnt activa- tion. Blood. 2013;122(21):61.
34. Rashidi A, Uy GL. Targeting the microenvi- ronment in acute myeloid leukemia. Curr Hematol Malig Rep. 2015;10(2):126-131.
35.Morita K, Tokushige C, Maeda S, et al. RUNX transcription factors potentially con-
36.
trol E-selectin expression in the bone mar- row vascular niche in mice. Blood Adv. 2018;2(5):509-515.
Barbier V, Erbani J, Fiveash C, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by dis- rupting vascular niche-mediated chemore- sistance. Nat Commun. 2020;11(1):2042.
3406.
46.Cortes JE, Tallman MS, Schiller GJ, et al.
Phase 2b study of two dosing regimens of quizartinib monotherapy in FLT3-ITD mutated, relapsed or refractory AML. Blood. 2018;132(6):598-607.
47. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18 (8):1061-1075.
48.Paschka P, Schlenk RF, Weber D, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia- results of the AMLSG 11-08 trial. Leukemia. 2018;32(7):1621-1630.
49. Katsumi A, Kiyoi H, Abe A, et al. FLT3/ ITD regulates leukaemia cell adhesion through alpha4beta1 integrin and Pyk2 signalling. Eur J Haematol. 2011;86(3):191-198.
50. Lu Y, Yu Q, Liu JH, et al. Src family protein- tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3- kinase/AKT cascades. J Biol Chem. 2003;278(41):40057-40066.
51. Roversi FM, Pericole FV, Machado-Neto JA, et al. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of ery- thropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway. Biochim Biophys Acta. 2017;1863 (2):450-461.
52. Zhu QS, Xia L, Mills GB, Lowell CA, Touw IP, Corey SJ. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood. 2006;107(5):1847-1856.
37.Krause DS, Lazarides K, Lewis JB, et al. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood. 2014;123(9):1361-1371.
38. Godavarthy PS, Kumar R, Herkt SC, et al. The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. Haematologica. 2020;105(1):136-147.
39. Malfuson JV, Boutin L, Clay D, et al. SP/drug efflux functionality of hematopoietic pro- genitors is controlled by mesenchymal niche through VLA-4/CD44 axis. Leukemia. 2014;28(4):853-864.
40. Yago T, Shao B, Miner JJ, et al. E-selectin engages PSGL-1 and CD44 through a com- mon signaling pathway to induce integrin alphaLbeta2-mediated slow leukocyte rolling. Blood. 2010;116(3):485-494.
41. Ilangumaran S, Briol A, Hoessli DC. CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in gly- cosphingolipid-rich plasma membrane domains of human peripheral blood lym- phocytes. Blood. 1998;91(10):3901-3908.
42. Lee JL, Wang MJ, Sudhir PR, Chen JY. CD44 engagement promotes matrix-derived sur- vival through the CD44-SRC-integrin axis in lipid rafts. Mol Cell Biol. 2008;28(18):5710- 5723.
43. Huveneers S, Danen EH. Adhesion signaling - crosstalk between integrins, Src and Rho. J Cell Sci. 2009;122(Pt 8):1059-1069.
44. Okamoto M, Hayakawa F, Miyata Y, et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treat- ment of AML with FLT3/ITD. Leukemia. 2007;21(3):403-410.
45. Levis M. Midostaurin approved for FLT3- mutated AML. Blood. 2017;129(26):3403-
53.
54.
Pillinger G, Loughran NV, Piddock RE, et al. Targeting PI3Kdelta and PI3Kgamma sig- nalling disrupts human AML survival and bone marrow stromal cell mediated protec- tion. Oncotarget. 2016;7(26):39784-39795. Su Y, Li X, Ma J, et al. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol. 2018; 148:13-26.
haematologica | 2021; 106(8)
2113